Professor & Chair (Endowed) - Molecular & Cellular Endocrinology

Location
Duarte, California
Salary
Competitive
Posted
September 12 2021
Ref
10012344-1
Position Type
Full Time
Organization Type
Healthcare/Hospital
City of Hope

Professor & Chair (with endowed chair)

Department of Molecular & Cellular Endocrinology

Arthur Riggs Diabetes & Metabolism Research Institute (AR-DMRI)

The Department of Molecular & Cellular Endocrinology within the Arthur Riggs Diabetes & Metabolism Research Institute (AR-DMRI) (https://www.cityofhope.org/research/diabetes-metabolism-research-institute) at City of Hope has an opening for a professor and department chair.

The AR-DMRI is a component of the Beckman Research Institute (BRI) at City of Hope (https://www.cityofhope.org/research/beckman-research-institute). City of Hope's research depth in diabetes and cancer is deemed an important differentiator, with opportunities for scientific and clinical distinction as well as collaboration across disciplines.

The successful candidate will be a nationally and internationally renowned scientist whose research program is at the forefront of molecular, cellular, immunological and/or inflammatory mechanisms relevant to type 1 and type 2 diabetes. Applicants must have a Ph.D. and/or M.D. and possess an exceptional record of scholarly accomplishments as evidenced by high-impact publications, substantial extramural funding and national and international awards. In addition, the position requires that the candidate also have demonstrated basic and translational program leadership and mentoring skills.

Exceptional interpersonal and communication skills are required, as s/he will be interacting with colleagues across City of Hope including students, researchers, clinical faculty and administrators. The department chair will work closely with leadership in the recruitment of new faculty to build and establish this exciting new department.

Minimum Qualifications and Skills Required for Consideration
  • Ph.D. and/or M.D.
  • Scholarly accomplishments to qualify for appointment at the rank of professor
  • Prominent research program at the interface of diabetes and cancer metabolism
  • National and international scientific leadership
  • Substantial extramural funding and productive results
  • Exceptional scientific and program leadership
  • Impactful mentoring skills
  • Strong classroom teaching skills
  • Interdisciplinary and inter-institutional collaboration
  • Demonstrated ability to lead highly trained researchers and multidisciplinary teams.
  • Exceptional interpersonal skills including relationship-building, communications, listening, negotiation diplomacy.
  • Practice a high level of integrity and honesty.
  • Ability to demonstrate inclusive behaviors.


To be considered for this position, please send a cover letter describing your interest, important research and related accomplishments, curriculum vitae and the names and addresses of five references to:

Arthur Riggs Diabetes Metabolism & Research Institute

c/o Debbie Niemi-Escalera

City of Hope

1500 E. Duarte Road

Duarte, CA 91010

Email: dniemi-escalera@coh.org

About City of Hope

City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as one of only 51 comprehensive cancer centers, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the world.

City of Hope is located in Duarte, California, just northeast of Los Angeles, with community clinics throughout Southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation, diabetes and numerous breakthrough cancer drugs based on technology developed at the institution.

City of Hope's Commitment to Diabetes Research

Bringing together the best in bench-to bedside research, City of Hope's Arthur Riggs Diabetes & Metabolism Research Institute (AR-DMRI) is one of the world's most comprehensive diabetes research programs.

City of Hope has a long and impressive history of groundbreaking discoveries in the field of diabetes spanning more than five decades of intense investigation since Rachmiel Levine , M.D., who discovered the role of insulin in glucose transport, launched diabetes research at City of Hope in the 1970s.

City of Hope's Arthur Riggs Diabetes & Metabolism Research Institute is named for Arthur D. Riggs , Ph.D., another pioneer in the field famous for his work on synthesizing the first man-made gene and using synthetic genes to produce human insulin. This first practical source of human insulin has become the standard of care for diabetes worldwide. The Riggs Institute is headed by Debbie Thurmond, Ph.D., a renowned research scientist, professor and founding chair of the Department of Molecular & Cellular Endocrinology .

City of Hope's Commitment to Diversity, Equity & Inclusion
  • We believe diversity is key in serving our mission to provide compassionate patient care, drive innovative discovery, and advance vital education focused on eliminating cancer and diabetes in all of our communities.
  • Our commitment to Diversity, Equity and Inclusion ensures we bring the full range of skills, perspectives, cultural backgrounds and experiences to our work -- and that our teams align with the people we serve in order to build trust and understanding.
  • We are dedicated to fostering a community that embraces diversity - in ideas, backgrounds and perspectives; this is reflected in our work and represented in our people.
  • We are proud to be an Equal Opportunity Employer.


In the News

NEWS RELEASES

CITY OF HOPE RENAMES WORLD-CLASS RESEARCH CENTER

HONORING ART RIGGS

INNOVATIVE CITY OF HOPE RESEARCH FEATURED AT 2021 ADA CONFERENCE

KIDNEY DISEASE AND DIABETES: SEARCHING FOR ANSWERS AT THE MOLECULAR LEVEL

DIABETES RESEARCHER HUNTS DOWN DISEASES EARLIEST TRACES

PHASE 1 TYPE 1 DIABETES INVESTIGATIONAL VACCINE TRIAL OPENS

RESEARCHERS IDENTIFY NEW TARGET FOR POTENTIAL TYPE 1 DIABETES TREATMENT

CITY OF HOPE AIMS TO CURE TYPE 1 DIABETES IN SIX YEARS

THE WANEK FAMILY PROJECT TO CURE TYPE 1 DIABETES: 18 MONTHS LATER

ISLET CELL TRANSPLANT HELPS DIABETES PATIENT PUT THREE DECADES OF COMPLICATIONS BEHIND HIM

FOR THIS DIABETES RESEARCHER, THE MISSION IS PERSONAL

CANCER AND DIABETES: MORE CONNECTIONS THAN YOU THINK

THE ENDURING LEGACY OF CITY OF HOPE'S JAPANESE-AMERICAN SCIENTISTS

CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE AWARDS CITY OF HOPE $5.74 MILLION FOR SEVERE SICKLE CELL DISEASE CLINICAL TRIAL

REELING IN THE PAST: RESEARCH GIVES NEW LIFE TO OLD MODEL OF DNA LOOPING

NEW CLUES COULD POINT TO BETTER TREATMENTS FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD)

BART ROEP, PH.D., HAS TYPE 1 DIABETES CURE IN HIS SIGHTS

STEM CELL TRANSPLANTS LEAD TO CURE FOR SOME TYPE 1 DIABETES PATIENTS FOR DIABETES PATIENTS, ISLET IMPLANTS IN SKIN SHOW PROMISE

Our Values

Compassion

We hold compassion at our very core. It's compassion that extends to and among our patients, their families and our team members.

It's compassion that takes form not only in the treatments we offer, but also in our tireless efforts in philanthropy and advocacy, our humanistic approach to research and care, and our dignified, day-to-day relationships with every individual we encounter.

Service With a Sense of Urgency

We focus on turning great science into practical benefit - as quickly and as powerfully as possible.

Driven to provide new treatments for more and more people each day, we tenaciously pursue new and better ways to improve the lives of people around the world. Our passion for serving others extends to our own staff of experts - because providing our own team members with opportunities to strengthen communities helps all of us work more effectively.

Integrity

We choose the right path - not the easy one. We promote a "just culture" environment that requires each of us to ensure the safety of those we serve. That means we do what's best for our patients, and for our community, every moment of every day.

Integrity guides our passionate engagement in our work, and it fuels our collective ability to conduct our business with transparency. We hold ourselves accountable for each of our commitments, and we'll always strive to do the right thing.

Intellectual Curiosity

Our long-standing reputation for scientific excellence stems from a determination to aggressively pursue new lines of inquiry. In spite of all of our successes, complacency is never an option. We are lifelong learners who are committed to moving discovery forward for the benefit of patients and for the health of the scientific community worldwide. We have created, and will continue to create, life-changing moments and life-saving breakthroughs - including the development of the first synthetic human insulin, as well as the introductions of numerous cancer-fighting drugs.

Excellence

Coupled with our compassionate care, our commitment to the advancement of science has established us as the standard bearer in the fights against diabetes, cancer and other life-threatening diseases. Without ever compromising safety, we strive for excellence in our processes and outcomes. We encourage each expert on our team to use his or her best judgment while making decisions that align with our mission, our values and our worldwide reputation for excellence.

Collaboration

Our work is challenging - but our common purpose moves us toward remarkable achievements that are changing the lives of others. As a synergistic community of experts, we regularly combine the resources of cutting-edge scientific research, drug manufacturing, clinical care, graduate education, philanthropy and supportive care services.

And we're proud of the results.

Recognizing the value of bringing together diverse perspectives, we promote grand new partnerships and the free exchange of knowledge - an exchange that brings the best possible minds together for a powerful common purpose.

  • Posting Date: Jul 15, 2021
  • Job Field: Research
  • Employee Status: Regular
  • Shift: Day Job

Similar jobs

Similar jobs